컨텐츠 바로가기
파이프라인 개요 Targeting, Attacking, and Eradicating Cancers®

TOP

파이프라인 개요 신라젠에서 개발중인 적응증 확대 및 병용치료법 연구현황 적응증 확대 및 병용치료법 개발

Pipelines
Preclinical
Phase 1
Phase 2
Phase 3
Mitotic Checkpoint Inhibitor
BAL0891 (monotherapy)
Advanced Solid Tumor
Substudy 1
+
BAL0891 + Tislelizumab (PD1 inhibitor)
Advanced Solid Tumor
Substudy 2
+
BAL0891 + Paclitaxel
Advanced Solid Tumor
Substudy 3
+
BAL0891 (monotherapy)
Acute Myeloid Leukemia
Substudy 4
+
Oncolytic Virus (platform)
SJ-650
Solid Tumor
Next pipelines under development
Solid Tumor
+
Oncolytic Virus
Pexa-Vec + Cemiplimab (PD1 inhibitor)
Renal Cell Carcinoma
Phase 1b/2a
+